HDAC9 and Huntington disease: Further work using an HD mouse model with slower progression, intervention earlier in the time course of pathology, a longer treatment regime with various doses or a combination of these factors in a well-powered sex-balanced cohort may enhance the leveraging of the therapeutic potentials of this selective HDAC inhibitor in HD.